Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor: early-phase trial registry
104 of 197 indexed Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #53 of 28,707 conditions by registered trial count.
197 US clinical trials · 104 currently recruiting · #53 of 28,707 conditions by registered trial count
Solid Tumor: 197 US clinical trials tracked, 104 recruiting.
Solid Tumor is the subject of 197 registered US clinical trials on ClinicalTrials.gov, 104 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 165 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition solid-tumor
OPEN 104 | RECR 53% | LATE 4 | EARLY 165 | RANK #53 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Metastatic Breast Cancer (53% recruiting · 140 trials)
Solid Tumor lists 104 open slots (53% of 197 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumor is recruiting above its size-band peers.
104 of 197 indexed trials (52.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumor trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 11 of 197 trials (5.6%). 149 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumor enrolment sits around 80 participants.
Median target enrolment is 80 among the 197 trials that report a genuine target (sentinel values excluded). 108 of those (54.8%) plan for fewer than 100 participants.
-
Solid Tumor research is mostly interventional.
179 interventional and 18 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
197 total, page 3 of 4
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Peter Zage
NCT03611595
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
NCT04541108
PET [89Zr]DFO-starPEG in Solid Tumors
Robert Flavell, MD, PhD
NCT06894745
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Virogin Biotech Canada
NCT05266612
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics
NCT05653882
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Invitae Corporation
NCT05219734
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences
NCT05544552
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland
NCT03229200
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Klus Pharma
NCT05642780
A Study of LY3200882 in Participants With Solid Tumors
Eli Lilly and Company
NCT02937272
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech
NCT03006172
Study of GS-4528 in Adults With Solid Tumors
Gilead Sciences
NCT05840224
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Astellas Pharma
NCT06364696
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co
NCT05627063
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT05736731
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe
NCT05199272
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics
NCT04205227
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics
NCT04931823
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience
NCT05103358
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
NCT02608385
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Saturn
NCT05128487
Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers
City of Hope Medical Center
NCT02041416
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics
NCT06105021
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
NCT00479128
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT04074967
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05678010
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
NCT04552288
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte
NCT04452955
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Sirnaomics
NCT05037149
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT03560882
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05566574
Study of PYX-106 in Solid Tumors
Pyxis Oncology
NCT05718557
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
HUYABIO International
NCT05485974
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HUYABIO International
NCT05163028
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Institut de Recherches Internationales Servier
NCT05162755
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT04419532
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT05704985
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03875287
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad
NCT03647163
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
NCT05672459
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics
NCT05076552
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals
NCT03865082
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio
NCT04050709
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT02932280
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06710847
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
NCT05103631
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Nucleix
NCT04264767
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 150 |
| Phase 2 | 15 |
| Phase 3 | 1 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumor page
197 registered trials, 104 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 104 Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor condition card totals 197 registered trials; most-linked intervention Nivolumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.